Key facts
- TXG - 10x Genomics, Inc. has 14 insiders with reported activity on this page.
- Net insider value flow over the last year: -$2,764,919.
- Recent transaction rows are available for direct filing-level review.
Insider Transactions Reported by 14 Insiders of 10x Genomics, Inc.
- Symbol
- TXG on Nasdaq
- Location
- Pleasanton, CA
Change
- Buy value: ; sell value: $2,764,918.
- Net share flow: -163,610.
Research use
- This page gives a plain-language issuer insider context before you inspect transaction-level evidence.
- Use the filing links below to verify timestamps, codes, and ownership impacts directly from SEC forms.
Evidence
Filed on Form 4
See Original Filing
Issuer insider activity is sourced from SEC Forms 3, 4, and 5.
Insider trading overview
Last 12 monthsNet insider flow leans to selling over the last 12 months. Net value: -$2,764,919.
Buys
$0
Shares: 0
Insiders: 0
Sells
$2,764,919
Shares: 163,610
Insiders: 4
Net
-$2,764,919
Shares: -163,610
Insiders: -4
| Window (months) | Buy shares | Sell shares | Buy $ | Sell $ | Net $ |
|---|---|---|---|---|---|
| 0-3 | 0 | 70,157 | $0 | $1,416,797 | -$1,416,797 |
| 3-6 | 0 | 33,432 | $0 | $635,151 | -$635,151 |
| 6-9 | 0 | 39,149 | $0 | $539,747 | -$539,747 |
| 9-12 | 0 | 20,872 | $0 | $173,223 | -$173,223 |
10x Genomics, Inc. executives and other stock owners filed with the SEC include:
| Name | Relationship | Holdings Value | Past Year Net Change | Change % | Valuation | Report Date |
|---|---|---|---|---|---|---|
| Bryan E. Roberts | Director | $195,830,277 | Mixed | 14 Jun 2023 | ||
| Serge Saxonov | Chief Executive Officer, Director | $93,276,505 | -$1,416,075 | -1.5% | Mixed | 14 Apr 2026 |
| Benjamin J. Hindson | Title: President and Chief Scientific Officer, Director | $10,826,582 | -$468,072 | -4.1% | Mixed | 26 Feb 2026 |
| Adam Taich | Chief Financial Officer | $8,326,515 | -$733,664 | -8.1% | Mixed | 26 Feb 2026 |
| Bradford Crutchfield | former officer | $4,438,548 | Mixed | 29 Jul 2022 | ||
| Mathai Mammen | Director | $4,380,943 | Mixed | 11 Jun 2024 | ||
| James Wilbur | Chief Commercial Officer | $3,804,287 | Mixed | 22 Nov 2023 | ||
| John R. Stuelpnagel | Director | $3,412,670 | Mixed | 03 Jun 2025 | ||
| Justin J. McAnear | Former Chief Financial Officer | $3,227,199 | Filing P/S | 22 Aug 2024 | ||
| Alan Mateo | Director | $731,185 | Mixed | 03 Jun 2025 | ||
| Sridhar Kosaraju | Director | $564,171 | Mixed | 03 Jun 2025 | ||
| Sarah A. Teichmann | Director | $519,799 | -$147,108 | -22% | Filing P/S | 25 Feb 2026 |
| Shehnaaz Suliman | Director | $271,565 | Mixed | 03 Jun 2025 | ||
| Kimberly J. Popovits | Director | $271,565 | Mixed | 03 Jun 2025 |
Top shareholders of 10x Genomics, Inc. (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| FMR LLC |
13F
13D/G
|
Company |
16%
from 13D/G
|
17,740,972
|
$376,640,828 | — | 31 Mar 2026 | |
| VANGUARD GROUP INC |
13D/G
|
The Vanguard Group |
12%
|
13,274,332
|
$155,176,941 | $0 | 30 Sep 2025 | |
| ARK Investment Management LLC |
13F
13D/G
|
Company |
10%
from 13D/G
|
11,717,317
|
$248,758,647 | — | 31 Mar 2026 | |
| BlackRock, Inc. |
13F
13D/G
|
Company |
7.6%
from 13D/G
|
10,079,913
|
$213,996,552 | — | 31 Mar 2026 | |
| Sumitomo Mitsui Trust Group, Inc. |
13F
13D/G
|
Company |
4.7%
from 13D/G
|
5,110,214
|
$108,489,843 | — | 31 Mar 2026 | |
| Amova Asset Management Americas, Inc. |
13F
13D/G
|
Company |
4.7%
from 13D/G
|
5,104,178
|
$108,310,657 | — | 31 Mar 2026 | |
| MILLENNIUM MANAGEMENT LLC |
13F
13D/G
|
Company |
2.7%
from 13D/G
|
2,068,414
|
$43,912,429 | — | 31 Mar 2026 | |
| Benjamin J. Hindson |
3/4/5
|
Title: President and Chief Scientific Officer, Director |
0.43%
|
513,595
|
$10,826,582 | -$468,072 | 26 Feb 2026 | |
| Adam Taich |
3/4/5
|
Chief Financial Officer |
0.33%
|
394,996
|
$8,326,515 | -$733,664 | 26 Feb 2026 | |
| John R. Stuelpnagel |
3/4/5
|
Director |
0.3%
|
359,607
|
$3,412,670 | — | 03 Jun 2025 | |
| Alan Mateo |
3/4/5
|
Director |
0.06%
|
77,048
|
$731,185 | — | 03 Jun 2025 | |
| Sridhar Kosaraju |
3/4/5
|
Director |
0.05%
|
59,449
|
$564,171 | — | 03 Jun 2025 | |
| Kimberly J. Popovits |
3/4/5
|
Director |
0.02%
|
28,616
|
$271,565 | — | 03 Jun 2025 | |
| Shehnaaz Suliman |
3/4/5
|
Director |
0.02%
|
28,616
|
$271,565 | — | 03 Jun 2025 | |
| Sarah A. Teichmann |
3/4/5
|
Director |
0.02%
|
26,780
|
$519,799 | -$147,108 | 25 Feb 2026 | |
| VANGUARD PORTFOLIO MANAGEMENT LLC |
13F
|
Company |
5.8%
|
6,912,936
|
$146,761,631 | — | 31 Mar 2026 | |
| Quantinno Capital Management LP |
13F
|
Company |
4.6%
|
5,411,761
|
$114,891,686 | — | 31 Mar 2026 | |
| VANGUARD CAPITAL MANAGEMENT LLC |
13F
|
Company |
4.4%
|
5,269,586
|
$111,873,311 | — | 31 Mar 2026 | |
| GOLDMAN SACHS GROUP INC |
13F
|
Company |
3.3%
|
3,971,800
|
$84,321,314 | — | 31 Mar 2026 | |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
|
Company |
2.4%
|
2,904,228
|
$61,669,469 | — | 31 Mar 2026 | |
| MORGAN STANLEY |
13F
|
Company |
2.2%
|
2,656,353
|
$56,394,400 | — | 31 Mar 2026 | |
| STATE STREET CORP |
13F
|
Company |
2.2%
|
2,588,795
|
$54,960,118 | — | 31 Mar 2026 | |
| AQR CAPITAL MANAGEMENT LLC |
13F
|
Company |
2.1%
|
2,538,256
|
$53,658,731 | — | 31 Mar 2026 | |
| JACOBS LEVY EQUITY MANAGEMENT, INC |
13F
|
Company |
1.9%
|
2,283,424
|
$48,477,092 | — | 31 Mar 2026 | |
| Casdin Capital, LLC |
13F
|
Company |
1.9%
|
2,275,000
|
$48,298,250 | — | 31 Mar 2026 | |
| DIMENSIONAL FUND ADVISORS LP |
13F
|
Company |
1.7%
|
2,042,950
|
$43,356,785 | — | 31 Mar 2026 | |
| Capital World Investors |
13F
|
Company |
1.2%
|
1,452,300
|
$30,832,329 | — | 31 Mar 2026 | |
| T. Rowe Price Investment Management, Inc. |
13F
|
Company |
1.1%
|
1,279,382
|
$27,162,000 | — | 31 Mar 2026 | |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC |
13F
|
Company |
0.95%
|
1,127,056
|
$23,927,399 | — | 31 Mar 2026 | |
| Blue Water Life Science Advisors, LP |
13F
|
Company |
0.92%
|
1,090,000
|
$23,140,700 | — | 31 Mar 2026 | |
| NORTHERN TRUST CORP |
13F
|
Company |
0.88%
|
1,048,005
|
$22,249,147 | — | 31 Mar 2026 | |
| RENAISSANCE TECHNOLOGIES LLC |
13F
|
Company |
0.85%
|
1,008,739
|
$21,415,529 | — | 31 Mar 2026 | |
| BALYASNY ASSET MANAGEMENT L.P. |
13F
|
Company |
0.83%
|
989,522
|
$21,007,552 | — | 31 Mar 2026 | |
| BANK OF AMERICA CORP /DE/ |
13F
|
Company |
0.81%
|
964,579
|
$20,478,002 | — | 31 Mar 2026 | |
| Connor, Clark & Lunn Investment Management Ltd. |
13F
|
Company |
0.79%
|
938,408
|
$19,922,402 | — | 31 Mar 2026 | |
| JPMORGAN CHASE & CO |
13F
|
Company |
0.66%
|
785,505
|
$15,560,855 | — | 31 Mar 2026 | |
| VANGUARD FIDUCIARY TRUST CO |
13F
|
Company |
0.66%
|
778,906
|
$16,536,174 | — | 31 Mar 2026 | |
| CITADEL ADVISORS LLC |
13F
|
Company |
0.63%
|
743,734
|
$15,789,473 | — | 31 Mar 2026 | |
| IEQ CAPITAL, LLC |
13F
|
Company |
0.59%
|
700,684
|
$14,875,515 | — | 31 Mar 2026 | |
| Freshford Capital Management, LLC |
13F
|
Company |
0.57%
|
672,956
|
$14,286,857 | — | 31 Mar 2026 | |
| Nuveen, LLC |
13F
|
Company |
0.53%
|
625,796
|
$13,285,650 | — | 31 Mar 2026 | |
| FEDERATED HERMES, INC. |
13F
|
Company |
0.51%
|
611,614
|
$12,984,566 | — | 31 Mar 2026 | |
| IQ EQ FUND MANAGEMENT (IRELAND) Ltd |
13F
|
Company |
0.46%
|
542,757
|
$11,522,731 | — | 31 Mar 2026 | |
| Trexquant Investment LP |
13F
|
Company |
0.45%
|
533,288
|
$11,321,704 | — | 31 Mar 2026 | |
| Meridiem Capital Partners LP |
13F
|
Company |
0.44%
|
523,998
|
$11,124,478 | — | 31 Mar 2026 | |
| VOLORIDGE INVESTMENT MANAGEMENT, LLC |
13F
|
Company |
0.42%
|
497,157
|
$10,554,643 | — | 31 Mar 2026 | |
| UBS Group AG |
13F
|
Company |
0.42%
|
494,762
|
$10,503,797 | — | 31 Mar 2026 | |
| Sands Capital Alternatives, LLC |
13F
|
Company |
0.41%
|
481,770
|
$10,227,977 | — | 31 Mar 2026 | |
| Russell Investments Group, Ltd. |
13F
|
Company |
0.4%
|
480,619
|
$10,203,553 | — | 31 Mar 2026 | |
| Quantedge Capital Pte Ltd |
13F
|
Company |
0.35%
|
416,553
|
$8,843,420 | — | 31 Mar 2026 |
Recent Insider Transactions by Companies or Individuals for 10x Genomics, Inc.
Showing up to 300 most recent insider transactions from the last 12 months.
| Insider | Symbol | Class | Transaction | % | Value $ | * Price $ | Shares | Shares Owned | Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|
| Serge Saxonov | TXG | Class A Common Stock | Sale | -0.43% | $122,784 | $24.56 | -5,000 | 1,167,273 | 14 Apr 2026 | Direct |
| Serge Saxonov | TXG | Class A Common Stock | Sale | -0.42% | $97,612 | $19.52 | -5,000 | 1,172,273 | 24 Mar 2026 | Direct |
| Serge Saxonov | TXG | Class A Common Stock | Sale | -0.84% | $191,297 | $19.13 | -10,000 | 1,177,273 | 23 Mar 2026 | Direct |
| Serge Saxonov | TXG | Class A Common Stock | Gift | -0.23% | -2,750 | 1,200,917 | 03 Mar 2026 | Direct | ||
| Serge Saxonov | TXG | Class A Common Stock | Sale | -1.32% | $367,097 | $22.73 | -16,152 | 1,203,667 | 02 Mar 2026 | Direct |
| Serge Saxonov | TXG | Class A Common Stock | Award | 14.9% | 157,895 | 1,219,819 | 26 Feb 2026 | Direct | ||
| Benjamin J. Hindson | TXG | Class A Common Stock | Award | 20.9% | 88,816 | 513,595 | 26 Feb 2026 | Direct | ||
| Adam Taich | TXG | Class A Common Stock | Award | 37% | 106,579 | 394,996 | 26 Feb 2026 | Direct | ||
| Sarah A. Teichmann | TXG | Class A Common Stock | Sale | -22.1% | $147,108 | $19.41 | -7,579 | 26,780 | 25 Feb 2026 | Direct |
| Serge Saxonov | TXG | Class A Common Stock | Sale | -0.9% | $178,928 | $18.58 | -9,632 | 1,061,924 | 23 Feb 2026 | Direct |
| Adam Taich | TXG | Class A Common Stock | Sale | -3.02% | $166,593 | $18.58 | -8,968 | 288,417 | 23 Feb 2026 | Direct |
| Benjamin J. Hindson | TXG | Class A Common Stock | Sale | -1.81% | $145,379 | $18.58 | -7,826 | 424,779 | 23 Feb 2026 | Direct |
| Serge Saxonov | TXG | Class A Common Stock | Options Exercise | 4.89% | 50,000 | 1,071,556 | 05 Jan 2026 | Direct | ||
| Serge Saxonov | TXG | Stock Option (right to buy) | Options Exercise | -100% | -50,000 | 0 | 05 Jan 2026 | Direct | ||
| Adam Taich | TXG | Class A Common Stock | Sale | -3.84% | $225,852 | $19.00 | -11,888 | 297,385 | 24 Nov 2025 | Direct |
| Benjamin J. Hindson | TXG | Class A Common Stock | Sale | -1.88% | $157,363 | $19.00 | -8,283 | 432,605 | 24 Nov 2025 | Direct |
| Serge Saxonov | TXG | Class A Common Stock | Sale | -1.28% | $251,936 | $19.00 | -13,261 | 1,021,556 | 24 Nov 2025 | Direct |
| Serge Saxonov | TXG | Class A Common Stock | Gift | -0.09% | -900 | 1,034,817 | 12 Sep 2025 | Direct | ||
| Serge Saxonov | TXG | Class A Common Stock | Sale | -0.98% | $128,881 | $13.79 | -9,348 | 945,892 | 22 Aug 2025 | Direct |
| Adam Taich | TXG | Class A Common Stock | Sale | -6.73% | $307,657 | $13.79 | -22,315 | 309,273 | 22 Aug 2025 | Direct |
| Benjamin J. Hindson | TXG | Class A Common Stock | Sale | -1.67% | $103,209 | $13.79 | -7,486 | 440,888 | 22 Aug 2025 | Direct |
| Serge Saxonov | TXG | Class A Common Stock | Gift | -0.1% | -1,000 | 955,240 | 09 Jun 2025 | Direct | ||
| Sarah A. Teichmann | TXG | Class A Common Stock | Award | 80.8% | 15,357 | 34,359 | 03 Jun 2025 | Direct | ||
| Shehnaaz Suliman | TXG | Class A Common Stock | Award | 115.8% | 15,357 | 28,616 | 03 Jun 2025 | Direct | ||
| John R. Stuelpnagel | TXG | Class A Common Stock | Award | 4.46% | 15,357 | 359,607 | 03 Jun 2025 | Direct | ||
| Kimberly J. Popovits | TXG | Class A Common Stock | Award | 115.8% | 15,357 | 28,616 | 03 Jun 2025 | Direct | ||
| Alan Mateo | TXG | Class A Common Stock | Award | 24.9% | 15,357 | 77,048 | 03 Jun 2025 | Direct | ||
| Sridhar Kosaraju | TXG | Class A Common Stock | Award | 37.4% | 15,357 | 56,449 | 03 Jun 2025 | Direct | ||
| Serge Saxonov | TXG | Class A Common Stock | Gift | -0.28% | -3,000 | 1,080,625 | 29 May 2025 | Direct | ||
| Serge Saxonov | TXG | Class A Common Stock | Sale | -0.85% | $77,540 | $8.30 | -9,343 | 1,083,625 | 22 May 2025 | Direct |
| Benjamin J. Hindson | TXG | Class A Common Stock | Sale | -1.64% | $62,120 | $8.30 | -7,485 | 448,374 | 22 May 2025 | Direct |
| Adam Taich | TXG | Class A Common Stock | Sale | -1.2% | $33,562 | $8.30 | -4,044 | 331,588 | 22 May 2025 | Direct |
* An asterisk sign (*) next to the price indicates that the price is likely invalid.